Sign inJoin waitlistJoin the waitlist

Behnam Badie

Chief, Division of Neurosurgery · City of Hope National Medical Center

Credentials: · · ·

History

Division of Neurosurgery · City of Hope National Medical Center
Present
Brain Tumor Program · City of Hope National Medical Center
Present

Neurological Surgery
UCLA David Geffen School of Medicine/UCLA Medical Center
1989–1996
David Geffen Sch of Med at UCLA
1985–1989

Research

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Case report · New England Journal of Medicine · 2016 · Last of 22 authors · 1,520 citations
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Clinical Cancer Research · 2015 · 643 citations
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
Nature Medicine · 2024 · Last of 30 authors · 302 citations

Jana Portnow
19 papers
Massimo D'Apuzzo
19 papers
Stephen Forman
16 papers
JR
Julie Ressler
8 papers
MC
Mike Chen
7 papers
Victor Haughton
6 papers
Aaron Field
5 papers · 1 as a fellow
JS
Jessica Sosso
5 papers
AC
Ammar Chaudhry
4 papers
RJ
Rahul Jandial
4 papers
SL
Samir Lapsiwala
4 papers · 4 as a resident
Analiz Rodriguez
3 papers · 3 as a resident

Grants

Targeting Glioblastoma with Multifunctional Anti-RAGE Oligonucleotides
National Institute of Neurological Disorders and Stroke · R01
Contact PI · $548.4K · Beckman Research Institute/City of Hope
2026–2031
Novel Neurosurgical Device for Evacuation of Intracerebral Hematoma
National Institute of Neurological Disorders and Stroke · R01
Contact PI · $1.1M · Beckman Research Institute/City of Hope
2025–2030
Improving Glioma Immunotherapy Efficacy by Regulating Tumor Inflammation
National Institute of Neurological Disorders and Stroke · R01
Contact PI · $2.2M · Beckman Research Institute/City of Hope
2023–2028
Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability
National Cancer Institute · U19
PI · $5.3M · Beckman Research Institute/City of Hope
2021–2027

Clinical trials

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
Principal investigator · Recruiting · Phase 1
City of Hope Medical Center
2026–2031
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
Principal investigator · Recruiting · Phase 1
City of Hope Medical Center
2025–2030
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
Principal investigator · Active not recruiting · Phase 1
City of Hope Medical Center
2020–2028
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
Principal investigator · Active not recruiting · Phase 1
City of Hope Medical Center
2019–2026